SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ:CYTX) reports financial results for the quarter ended September 30, 2007 and provides an update on recent developments and plans for commercialization. “Marketing of the Celution™ System has begun,” said Christopher J. Calhoun, chief executive officer. “Cytori and Green Hospital Supply have initiated commercialization efforts and intend to install the first Celution™-based StemSource™ Cell Bank in early 2008. In addition, we started commercial activities in Europe for the Celution™ market introduction in the first quarter of next year for reconstructive surgery. These efforts will be supported through two breast reconstruction post-marketing studies, RESTORE II and VENUS, which will begin in 2008. In parallel, we continue to move our product development pipeline forward, as approval was received to begin our APOLLO heart attack study and enrollment continues for the PRECISE chronic heart disease trial.”
